139 related articles for article (PubMed ID: 25421679)
1. Identification and characterization of small-molecule inhibitors of lysine acetyltransferases.
Liao D
Methods Mol Biol; 2015; 1238():539-48. PubMed ID: 25421679
[TBL] [Abstract][Full Text] [Related]
2. Identification of structural features of 2-alkylidene-1,3-dicarbonyl derivatives that induce inhibition and/or activation of histone acetyltransferases KAT3B/p300 and KAT2B/PCAF.
Castellano S; Milite C; Feoli A; Viviano M; Mai A; Novellino E; Tosco A; Sbardella G
ChemMedChem; 2015 Jan; 10(1):144-57. PubMed ID: 25333655
[TBL] [Abstract][Full Text] [Related]
3. Current development of CBP/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
5. KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.
Simon RP; Robaa D; Alhalabi Z; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1249-70. PubMed ID: 26701186
[TBL] [Abstract][Full Text] [Related]
6. The fluorescence-based acetylation assay using thiol-sensitive probes.
Gao T; Yang C; Zheng YG
Methods Mol Biol; 2013; 981():229-38. PubMed ID: 23381866
[TBL] [Abstract][Full Text] [Related]
7. Microfluidic Mobility Shift Profiling of Lysine Acetyltransferases Enables Screening and Mechanistic Analysis of Cellular Acetylation Inhibitors.
Sorum AW; Shrimp JH; Roberts AM; Montgomery DC; Tiwari NK; Lal-Nag M; Simeonov A; Jadhav A; Meier JL
ACS Chem Biol; 2016 Mar; 11(3):734-41. PubMed ID: 26428393
[TBL] [Abstract][Full Text] [Related]
8. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
9. Lysine acetyltransferase inhibitors: structure-activity relationships and potential therapeutic implications.
Fiorentino F; Mai A; Rotili D
Future Med Chem; 2018 May; 10(9):1067-1091. PubMed ID: 29676588
[TBL] [Abstract][Full Text] [Related]
10. Profiling Cellular Substrates of Lysine Acetyltransferases GCN5 and p300 with Orthogonal Labeling and Click Chemistry.
Han Z; Chou CW; Yang X; Bartlett MG; Zheng YG
ACS Chem Biol; 2017 Jun; 12(6):1547-1555. PubMed ID: 28426192
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin.
Ravindra KC; Selvi BR; Arif M; Reddy BA; Thanuja GR; Agrawal S; Pradhan SK; Nagashayana N; Dasgupta D; Kundu TK
J Biol Chem; 2009 Sep; 284(36):24453-64. PubMed ID: 19570987
[TBL] [Abstract][Full Text] [Related]
12. Chemoproteomic profiling of lysine acetyltransferases highlights an expanded landscape of catalytic acetylation.
Montgomery DC; Sorum AW; Meier JL
J Am Chem Soc; 2014 Jun; 136(24):8669-76. PubMed ID: 24836640
[TBL] [Abstract][Full Text] [Related]
13. A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.
Milite C; Feoli A; Sasaki K; La Pietra V; Balzano AL; Marinelli L; Mai A; Novellino E; Castellano S; Tosco A; Sbardella G
J Med Chem; 2015 Mar; 58(6):2779-98. PubMed ID: 25730130
[TBL] [Abstract][Full Text] [Related]
14. Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor.
Modak R; Basha J; Bharathy N; Maity K; Mizar P; Bhat AV; Vasudevan M; Rao VK; Kok WK; Natesh N; Taneja R; Kundu TK
ACS Chem Biol; 2013; 8(6):1311-23. PubMed ID: 23570531
[TBL] [Abstract][Full Text] [Related]
15. Histone acetyl transferases as emerging drug targets.
Dekker FJ; Haisma HJ
Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
[TBL] [Abstract][Full Text] [Related]
16. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
17. Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors.
Huhn AJ; Gardberg AS; Poy F; Brucelle F; Vivat V; Cantone N; Patel G; Patel C; Cummings R; Sims R; Levell J; Audia JE; Bommi-Reddy A; Wilson JE
ChemMedChem; 2020 Jun; 15(11):955-960. PubMed ID: 32181984
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules.
Arif M; Pradhan SK; Thanuja GR; Vedamurthy BM; Agrawal S; Dasgupta D; Kundu TK
J Med Chem; 2009 Jan; 52(2):267-77. PubMed ID: 19086895
[TBL] [Abstract][Full Text] [Related]
19. The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target.
Di Martile M; Del Bufalo D; Trisciuoglio D
Oncotarget; 2016 Aug; 7(34):55789-55810. PubMed ID: 27322556
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
Chaikuad A; Lang S; Brennan PE; Temperini C; Fedorov O; Hollander J; Nachane R; Abell C; Müller S; Siegal G; Knapp S
J Med Chem; 2016 Feb; 59(4):1648-53. PubMed ID: 26731131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
